Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $5.2 million.

  • Rhythm Pharmaceuticals' Gains from Investment Securities rose 67731.28% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.6 million, marking a year-over-year increase of 97592.77%. This contributed to the annual value of $6.6 million for FY2024, which is 92.15% up from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Gains from Investment Securities of $5.2 million as of Q3 2025, which was up 67731.28% from -$5.4 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Gains from Investment Securities peaked at $27.9 million during Q4 2024, and registered a low of -$5.4 million during Q2 2025.
  • Its 5-year average for Gains from Investment Securities is $1.7 million, with a median of $1500.0 in 2022.
  • Within the past 5 years, the most significant YoY rise in Rhythm Pharmaceuticals' Gains from Investment Securities was 69745000.0% (2024), while the steepest drop was 130707.07% (2024).
  • Over the past 5 years, Rhythm Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $1.3 million in 2021, then tumbled by 100.08% to -$1000.0 in 2022, then skyrocketed by 500.0% to $4000.0 in 2023, then skyrocketed by 697450.0% to $27.9 million in 2024, then tumbled by 81.21% to $5.2 million in 2025.
  • Its last three reported values are $5.2 million in Q3 2025, -$5.4 million for Q2 2025, and -$102000.0 during Q1 2025.